Risk factors for lenvatinib-induced hypertension in patients with hepatocellular carcinoma: A retrospective study.

ABSTRACT:

Aims

Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). LEN therapy for HCC is associated with a high incidence of adverse events, including hypertension (HTN). However, the risk factors associated with LEN therapy remain unclear. This study investigated the incidence of LEN-induced HTN (LENiHTN), and the relationship between HTN incidence and patient demographics in patients with HCC receiving LEN therapy.

Methods

This was a single-centre, retrospective study of patients with HCC who received LEN therapy between 19 April 2018 and 30 September 2020. The observation period was from 1 week before the start to 1 month after the end of LEN administration.

Results

Seventy-fi

SUBMITTER: Uekusa S 

PROVIDER: S-EPMC11862797 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature